Hu Wei1, Chunnian He, Yong Peng, Guoxu Ma, Peigen Xiao. 1. Institute of Medicinal Plant Development, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100193, China. weihua20@126.com
Abstract
OBJECTIVE: To study the chemical constituents of Dolomiaea souliei. METHOD: Various chromatographic techniques were adopted to separate the constituents, and the spectrum analysis was made to identify their structures. RESULT: Seventeen compounds were isolated and identified as: dehydrocostus lactone (1), costunolide (2), mokko lactone (3), santamarine(4), reynosin (5), 4alpha-hydroxy-4beta-methyldihydrocostol (6), sulfocostunolide A (7), beta-costic acid (8), beta-cyclocostunolide (9), vladinol A (10), ursolic acid (11), betulinic acid (12), betulin (13), dibutyl terephthalate (14), dibutyl phthalate (15), uridine (16), and emodin (17). CONCLUSION: Compounds 6-9 and 12-17 were obtained from this genus for the first time, and compound 11 was obtained from this plant for the first time.
OBJECTIVE: To study the chemical constituents of Dolomiaea souliei. METHOD: Various chromatographic techniques were adopted to separate the constituents, and the spectrum analysis was made to identify their structures. RESULT: Seventeen compounds were isolated and identified as: dehydrocostus lactone (1), costunolide (2), mokko lactone (3), santamarine(4), reynosin (5), 4alpha-hydroxy-4beta-methyldihydrocostol (6), sulfocostunolide A (7), beta-costic acid (8), beta-cyclocostunolide (9), vladinol A (10), ursolic acid (11), betulinic acid (12), betulin (13), dibutyl terephthalate (14), dibutyl phthalate (15), uridine (16), and emodin (17). CONCLUSION: Compounds 6-9 and 12-17 were obtained from this genus for the first time, and compound 11 was obtained from this plant for the first time.
Authors: Miriéle Cristina Ferraz; Jhones Luiz de Oliveira; Joel Reis de Oliveira Junior; José Carlos Cogo; Márcio Galdino Dos Santos; Luiz Madaleno Franco; Pilar Puebla; Helena Onishi Ferraz; Humberto Gomes Ferraz; Marisa Maria Teixeira da Rocha; Stephen Hyslop; Arturo San Feliciano; Yoko Oshima-Franco Journal: Evid Based Complement Alternat Med Date: 2015-11-08 Impact factor: 2.629